Healthcare
Solventum Corporation(SOLV)
Live Price
Offline$75.43
+1.17% today
1Y Change
+10.50%
Window
Jun 23, 2025 โ Jun 10, 2026
- Market Cap
- $11.56B
- Revenue Growth
- +0.9%
- EPS Growth
- +222.7%
- Dividend Yield
- 0.0%
Coverage: 243 bars ยท Jun 23, 2025 โ Jun 10, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Solventum Corporation (SOLV) is a Healthcare stock with a market cap of $11.56B and listed on NYSE. The stock last traded around $75.43 and up 10.5% across the available one-year price window (Jun 23, 2025 โ Jun 10, 2026). Baseline metrics include revenue growth of +0.9%, EPS growth of +222.7%, a dividend yield of 0.0%. What stands out right now is revenue +0.9%, EPS +222.7%, free cash flow -101.2% with operating margin 26.2% and ROIC 17.8%. Valuation is more restrained than many high-expectation growth names at P/E 7.5 and price/sales 1.4. Stock Foundry combines SOLV price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+0.9% vs +7.6% peer median
Operating Margin
Above sector median
+26.2% vs +19.4% peer median
P/E
Below sector median
7.5 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +0.9% and EPS at +222.7%, with operating margin around 26.2%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +2.9% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -0.2% | +3.1% | โ |
2026 Feb 26, 2026 | +4.7% | -3.6% | -8.0% | -15.9% |
2025 Nov 6, 2025 | +4.9% | +7.9% | +13.5% | +28.9% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SOLV
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SOLV Max Drawdown
-27.46%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SOLV and SPY.
Company Overview
Solventum Corporation
New York Stock Exchange
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. The Dental Solutions segment provides a comprehensive suite of dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents. The Health Information Systems provides software solutions including computer-assisted, physician documentation, direct-to-bill and coding automation, classification methodologies, speech, recognition, and data visualization platforms. The Purification and Filtration segment provides purification and filtration technologies including filters, purifiers, cartridges, and membranes. The company was incorporated in 2023 and is based in Saint Paul, Minnesota.
- Leadership
- Bryan C. Hanson
- IPO Date
- Apr 1, 2024
- Employees
- 22.0k
- Street Address
- 3M Center
- Mailing
- Maplewood, MN, 55144
- Region
- Maplewood, MN, US
- Reporting Currency
- USD
- Investor Line
- 651-733-1110
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 7.5
- EV/EBITDA
- 5.6
- Price/Sales
- 1.4
- Price/Book
- 2.3
Growth
- Revenue
- +0.9%
- EPS
- +222.7%
- Free Cash Flow
- -101.2%
Profitability
- Gross Margin
- 53.5%
- Operating Margin
- 26.2%
- Net Margin
- 18.7%
- ROE
- 36.7%
- ROIC
- 17.8%
Balance Sheet
- Debt/Equity
- 1.00
- Current Ratio
- 1.23
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.